Study on CD117 and bcl-2 in Stomach Cancer
Author Information
Author(s): Mireskandari Masoud, Shafaii Ali Fakhr, Kayser Gian, Kayser Klaus
Primary Institution: Afzalipour Hospital, Pathology Department, Kerman University of Medical Sciences, Kerman, Iran
Hypothesis
This study was designed to immunohistochemically evaluate the CD117 and bcl-2 expression in gastric carcinomas and their potential use as therapeutic targets.
Conclusion
CD117 does not play a significant role in gastric carcinoma pathways and development, and bcl-2 expression is rare in gastric carcinomas.
Supporting Evidence
- None of the 38 gastric carcinoma cases displayed CD117 expression immunohistochemically.
- Bcl-2 expression was observed in only one case of diffuse gastric carcinoma.
- The majority of gastric carcinomas were immunohistochemically negative for both CD117 and bcl-2.
Takeaway
The study looked at two proteins in stomach cancer to see if they could be used to help treat patients, but found that they are not important.
Methodology
Immunohistochemical analysis was performed on paraffin blocks from 38 gastric adenocarcinoma patients.
Limitations
The study only evaluated the expression of CD117 and bcl-2 and did not explore other potential therapeutic targets.
Participant Demographics
Patients ranged in age from 23 to 88 years, with a mean age of 56; the sex ratio was 1.7:1 (men to women).
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website